Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning

JB Nilsson, S Kaabinejadian, H Yari, MGD Kester… - Science …, 2023 - science.org
Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II
molecules is crucial for rational development of immunotherapies and vaccines targeting …

[HTML][HTML] Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

J Racle, P Guillaume, J Schmidt, J Michaux, A Larabi… - Immunity, 2023 - cell.com
CD4+ T cells orchestrate the adaptive immune response against pathogens and cancer by
recognizing epitopes presented on class II major histocompatibility complex (MHC-II) …

[HTML][HTML] From clones to immunopeptidomes: new developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation

E Arrieta-Bolaños - Best Practice & Research Clinical Haematology, 2024 - Elsevier
Mismatching at the HLA-DPB1 locus occurs frequently in hematopoietic cell transplantation
with unrelated donors. Despite this, HLA-DPB1 allelic mismatches have traditionally not …

Tricking the trickster: precision medicine approaches to counteract leukemia immune escape after transplant

A Tameni, C Toffalori, L Vago - Blood, 2024 - ashpublications.org
Over the last decades, significant improvements in reducing the toxicities of allogeneic
hematopoietic cell transplantation (allo-HCT) have widened its use as consolidation or …

Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation

P Crivello, E Arrieta-Bolaños, M He, T Wang… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Immunopeptidome divergence between mismatched HLA-DP is a determinant of
T-cell alloreactivity and clinical tolerability after fully HLA-A,-B,-C,-DRB1,-DQB1 matched …

Human leukocyte antigen mismatching and survival in contemporary hematopoietic cell transplantation for hematologic malignancies

E Arrieta-Bolaños, EF Bonneville, P Crivello… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Human leukocyte antigen (HLA) mismatching can reduce survival of patients
with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in …

Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse

V Gambacorta, S Beretta, M Ciccimarra, L Zito… - Cancer …, 2022 - aacrjournals.org
Immune escape represents a major driver of acute myeloid leukemia (AML) reemergence
after allogeneic hematopoietic cell transplantation (allo-HCT), with up to 40% of relapses …

A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation

E Arrieta-Bolaños, P Crivello, M He… - Blood, The Journal …, 2022 - ashpublications.org
Clinically tolerable, permissive HLA-DPB1 mismatches defined by the T-cell epitope (TCE)
model improve the selection of unrelated donors in allogeneic hematopoietic cell …

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG

AT Turki, N Tsachakis-Mück, S Leserer… - Blood …, 2022 - ashpublications.org
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic
hematopoietic cell transplantation (HCT), whose impact on clinical outcome, in particular on …

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

NJ Hess, DP Turicek, J Riendeau, SJ McIlwain… - Science …, 2023 - science.org
An important paradigm in allogeneic hematopoietic cell transplantations (allo-HCTs) is the
prevention of graft-versus-host disease (GVHD) while preserving the graft-versus-leukemia …